The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Polycythemia Vera

SANDRA KURTIN, PhDc, ANP-C, AOCN®, and LINDSEY LYLE, MS, PA-C

From The University of Arizona Cancer Center, Tucson, Arizona; and University of Colorado Anschutz Medical Campus, Aurora, Colorado

Authors' disclosures of conflicts of interest are found at the end of this article.

Correspondence to: Sandra Kurtin, PhDc, ANP-C, AOCN®, The University of Arizona Cancer Center, 3838 North Campbell Avenue, Tucson, AZ 85719. Email: SandraKurtin@gmail.com

https://doi.org/10.6004/jadpro.2018.9.1.4
© 2018 Harborside™

CASE STUDY

Mr. M, a 65-year-old male, presented to his primary care physician with progressive fatigue, difficulty sleeping, and daily headaches for the past 3 weeks. His headaches were not associated with visual disturbances, cognitive deficits, or nausea/vomiting, and he had no history of migraines. He had a history of hypertension and hyperlipidemia, did not smoke, rarely drank alcohol, and had no recent illnesses or hospitalizations. His previous physical examination and laboratory studies 2 years ago were normal. The current physical examination revealed a plethoric yet well-appearing, well-nourished male in no acute distress. His lungs were clear to auscultation bilaterally without wheezes, rales, or rhonchi. He had a regular heart rate and rhythm without murmur. His abdomen was soft, without tenderness, distension, or palpable hepatosplenomegaly. Examination of the extremities was negative for edema. Distal pulses and sensation in the hands and feet were intact and equal bilaterally. Cranial nerves II to XII were deemed intact, and no gross focal deficits were observed. Complete blood count (CBC) revealed a slightly elevated white blood cell (WBC) count (14.6 × 10^9/L [normal range, 3.9–10.7 × 10^9/L; Wians, 2015]), erythrocytosis (red blood cell [RBC] count, 6.5 × 10^{12}/L [normal range, 4.2–5.9 × 10^{12}/L; Wians, 2015], hemoglobin, 19 g/dL [normal range, 14–17 g/dL; Wians, 2015], and hematocrit, 54.3% [normal range, 41%–51%; Wians, 2015]), thrombocytosis (platelet count, 500 × 10^9/L [normal range, 150–350 × 10^9/L; Wians, 2015]), and microcytosis (mean cell volume [MCV], 75 fL [80–100 fL; Wians, 2015]), which combined were cause for referral to a hematology/oncology clinic.

During his hematology/oncology evaluation, Mr. M described “never feeling rested” and being unable to sleep with uncertain snoring habits. He was experiencing itching during hot showers yet did not have rashes and had not recently introduced a new soap. He had no family history.
of blood disorders and no personal history of blood clots. The second CBC and laboratory tests confirmed erythrocytosis (RBC count, \(6.5 \times 10^{12}/\text{L}\); hemoglobin, 18.9 g/dL; hematocrit, 54%) and microcytosis (MCV, 75 fL). Serum iron (22 \(\mu\text{g/dL}\) [normal range, 60–160 \(\mu\text{g/dL}\)]) and ferritin (5 ng/mL [normal range, 15–200 ng/mL]) were suggestive of iron deficiency, serum erythropoietin was 8 mU/mL (normal range, 4.0–18.5 mU/mL), and a Janus kinase 2 (\(JAK2\)) mutation analysis was positive for \(JAK2\)\(V617F\). Platelet count remained \(500 \times 10^9/\text{L}\) and WBC count was \(10.2 \times 10^9/\text{L}\).

Although the WHO guidelines are the standard for diagnosing PV, they may not aid in identifying patients with masked PV, a condition characterized by \(JAK2\) mutations and PV-consistent bone marrow morphology, despite subthreshold hemoglobin levels (Barbui et al., 2014). Consequently, the 2016 WHO guidelines include lower thresholds for hemoglobin levels and inclusion of bone marrow results in the major criteria (Table 1).

**NATURAL HISTORY AND DISEASE BURDEN**

Mr. M presented with fatigue, headaches, pruritus, and difficulty sleeping. Patients with PV may also present with a thromboembolic event or other disease-related signs, including a palpable spleen (Tefferi et al., 2013). However, many patients are diagnosed asymptotically based on routine blood work (Passamonti, 2012). Iron deficiency may result from the expanding erythrocyte population with a lower-than-normal erythropoietin level, and may mask the diagnosis of PV (Kambali & Taj, 2016). As the disease progresses, patients are at risk for cardiovascular, thromboembolic, and hemorrhagic events and may develop solid malignancies (Marchioli et al., 2005; Tefferi et al., 2013). Polycythemia vera may also transform to myelofibrosis (MF), which is diagnosed by 2008 International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria (Table 2; Barosi et al., 2008), and/or transform to acute myeloid leukemia (AML), which is identifiable by \(\geq 20\%\) blasts in the peripheral blood or bone marrow as well as by extramedullary tumoral blast proliferation (myeloid sarcoma) per 2008 WHO criteria (Vardimanetal., 2009). Cardiovascular or thromboembolic events, solid malignancies, and disease transformation to MF or AML are the leading contributors to an increased mortality risk for patients with PV compared with the age- and sex-matched general population (Hultcrantz et al., 2012; Marchioli et al., 2005; Tefferi et al., 2013).
### Table 1. World Health Organization Diagnostic Criteria for Polycythemia Vera

| WHO 2008 PV Diagnostic Criteria<sup>a</sup> | WHO 2016 PV Diagnostic Criteria<sup>b</sup> |
|------------------------------------------|------------------------------------------|
| Major criteria                           |                                          |
| 1. Hemoglobin > 18.5 g/dL (men), > 16.5 g/dL (women) or Hemoglobin or hematocrit > 99th percentile of reference range for age, sex, or altitude of residence or Hemoglobin > 17 g/dL (men)/> 15 g/dL (women) if associated with a sustained increase of ≥ 2 g/dL from baseline that cannot be attributed to correction of iron deficiency or Elevated red cell mass > 25% above mean | 1. Hemoglobin > 16.5 g/dL (men), > 16.0 g/dL (women) or Hematocrit > 49% (men), > 48% (women) |
| 2. Presence of JAK2V617F or similar mutation | 2. Bone marrow trilineage myeloproliferation with pleomorphic megakaryocytes |
|                                          | 3. Presence of JAK2V617F or similar mutation |
| Minor criteria                           | Subnormal serum erythropoietin level     |
| 1. Bone marrow trilineage myeloproliferation |                                           |
| 2. Subnormal serum erythropoietin level |                                           |
| 3. Endogenous erythroid colony growth    |                                           |
| Diagnostic criteria                      |                                           |
| 1. Both major criteria and 1 minor criterion | 1. All 3 major criteria                  |
| or                                       | or                                       |
| 2. The first major criterion and 2 minor criteria | 2. The first 2 major criteria and the minor criterion |

Note. WHO = World Health Organization; PV = polycythemia vera.<br><sup>a</sup>Adapted with permission from Tefferi and Vardiman (2008).<br><sup>b</sup>Adapted with permission from Tefferi, Thiele, Vannucchi, and Barbui (2014); Arber et al. (2016).

### Table 2. International Working Group for Myelofibrosis Research and Treatment Criteria for Post-Polycythemia Vera Myelofibrosis

| Required criteria |
|-------------------|
| 1. Documentation of a previous diagnosis of PV as defined by the WHO criteria, reported in Table 1 |
| 2. Bone marrow fibrosis grade 2–3 (on 0–3 scale)<sup>a</sup> or grade 3–4 (on 0–4 scale)<sup>b</sup> |

| Additional criteria (2 are required) |
|-------------------------------------|
| 1. Anemia<sup>c</sup> or sustained loss of requirement of either phlebotomy (in the absence of cytoreductive therapy) or cytoreductive treatment for erythrocytosis |
| 2. A leukoerythroblastic peripheral blood picture |
| 3. Increasing splenomegaly defined as either an increase in palpable splenomegaly of ≥ 5 cm (distance of the tip of the spleen from the left costal margin) or the appearance of a newly palpable splenomegaly |
| 4. Development of ≥ 1 of 3 constitutional symptoms: > 10% weight loss in 6 months, night sweats, unexplained fever (> 37.5°C) |

Note. PV = polycythemia vera; WHO = World Health Organization. Adapted with permission from Barosi et al. (2008).<br><sup>a</sup>According to the European classification: diffuse, often coarse fiber network with no evidence of collagenization (negative trichrome stain) or diffuse, coarse fiber network with areas of collagenization (positive trichrome stain; Thiele et al., 2005).<br><sup>b</sup>According to the standard classification: diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis or diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis (Manoharan, Horsley, & Pitney, 1979).<br><sup>c</sup>Below the reference range for appropriate age, sex, and altitude considerations.
et al., 2013). Splenomegaly-associated symptoms, including early satiety, and abdominal discomfort are not uncommon in patients with PV (Emanuel et al., 2012). Based on patient-reported experiences, PV-related symptoms reduce QOL and may hinder activities of daily living and work productivity (Mesa et al., 2016a).

**MANAGEMENT**

**Treatment Goals**
The treatment goals for PV are to reduce thromboembolic and hemorrhagic risk, to manage disease-related symptoms, and to minimize the risk of fibrotic or leukemic transformation (Barbui et al., 2011). Patients with a history of thromboembolic events and those aged ≥ 60 years have increased thrombotic risk (Barbui et al., 2014; Vannucchi, 2014). In addition, the Cytoreductive Therapy in PV (CYTOPV) trial demonstrated the importance of controlling hematocrit and possibly WBC count. Maintaining a hematocrit < 45% was associated with a fourfold reduced risk of death from cardiovascular or thrombotic events compared with hematocrit maintenance between 45% and 55% (Marchioli et al., 2013). Similarly, WBC count < 7 × 10^9/L was associated with a fourfold reduced risk of major thrombosis compared with ≥ 11 × 10^9/L (Barbui et al., 2015). In our case, the patient presented at 65 years of age with a hematocrit of 54%, indicating high risk for thromboembolic events.

It is important that APs develop an evidence-based treatment plan (Figure 1). Patients should be monitored routinely for changes in hematocrit and blood count (Barbui et al., 2011), with the frequency dictated by the patient’s disease severity and risk of complications and/or progression. Those with stable blood count may require follow-up every 3 months, whereas some patients, including those with a recent diagnosis or change in treatment, may require weekly monitoring to achieve hematocrit control and appropriate dosing of cytoreductive therapy. Symptom burden should be regularly assessed with an objective instrument such as the MPN Symptom Assessment Form (Figure 2; Barbui et al., 2011; Scherber et al., 2011). Finally, it is important to address comorbidities and history of cardiovascular, thromboembolic, and hemorrhagic events. An emphasis should be placed on achieving optimal control of conventional cardiovascular risk factors (i.e., elevated cholesterol, current smoking status, diabetes mellitus, and high systolic blood pressure; Goff et al., 2014) and monitoring for signs of disease transformation to MF (Table 2) (Barosi et al., 2008) or AML (Vardiman et al., 2009).

**Case Study Continued**
Following diagnosis, Mr. M received weekly phlebotomies until hematocrit was < 45% and started low-dose aspirin (81 mg/d), as is recommended for patients with PV (Landolfi et al., 2004; Marchioli et al., 2013) unless specific contraindications to low-dose aspirin exist, such as extreme thrombocytosis (platelet count > 1,000 × 10^9/L), at which point acquired von Willebrand syndrome should be ruled out due to risk of bleeding (Tefferi & Barbui, 2015). Because his age was > 60 years, the patient was considered high risk for thrombosis, and therefore started cytoreductive therapy with hydroxyurea.

**Traditional Treatment Options**
Best practices should be used for phlebotomy, including temporary cessation of the phlebotomy or administration of intravenous fluids for hypotension or other phlebotomy-related symptoms (e.g., acute illness, dizziness, dehydration; Parker, Deel, & Arner, 2004). Patients who are high risk (≥ 60 years or with a history of thromboembolic events) should be started on cytoreductive therapy. Additionally, patients with poor disease control with aspirin and phlebotomy alone (continually elevated blood count and/or persistent signs or symptoms) may benefit from the addition of cytoreductive treatment (Barbui et al., 2011) with hydroxyurea (Fruchtman et al., 1997; Kiladjian, Chevret, Dosquet, Chomienne, & Rain, 2011) or interferon-α (Hasselbalch, 2011).

Hydroxyurea is often recommended for first-line cytoreductive therapy (Vannucchi, 2014); however, approximately 1 in 4 patients become resistant or intolerant (Alvarez-Lárran et al., 2012) per European LeukemiaNet (ELN) criteria (Table 3). Hydroxyurea resistance is associated with a 5.6-fold increased risk of death compared with hydroxyurea responders (Alvarez-Lárran et al., 2012). Approaches to the treatment of PV—includ-
ing indications, common adverse events, and clinical implications—are provided in Table 4.

Case Study Continued
Mr. M’s disease was successfully managed for a few years. In regular follow-up, the WBC count increased over the course of a year to $20 \times 10^9/L$, and the patient developed progressive fatigue, pruritus, and night sweats, despite administering hydroxyurea at the maximum tolerated dose, indicating hydroxyurea resistance.

Treatment Options for Patients With PV Resistant to or Intolerant of Hydroxyurea
Ruxolitinib (Jakafi [US] or Jakavi [non-US]) is the only agent approved by the US Food and Drug Administration (FDA) for patients with PV who have had an inadequate response to or are intolerant of hydroxyurea (Incyte Corporation, 2016) and by the European Medicines Agency (EMA) for adult patients with PV who are resistant to or intolerant of hydroxyurea (EMA, 2015). Although interferon-α is an effective treatment option for some patients, it is not indicated by the FDA or EMA for patients with PV. Long-term treatment with interferon-α may be challenging for some patients because of its inconvenience as an injectable medication and treatment-related adverse events, which may include chills, depression, diarrhea, fatigue, fever, headache, musculoskeletal pain, myalgia, nausea, and weight loss (Hassellbalch, 2011). For these reasons, we did not consider interferon-α for Mr. M.

Regulatory approval of the oral JAK1/JAK2 inhibitor ruxolitinib (Quintás-Cardama et al., 2010) was based on the randomized, open-label, multicenter phase III RESPONSE trial, which evaluated ruxolitinib vs. best available therapy (BAT; i.e., hydroxyurea, interferon-α, anagrelide, immunomodulators, pipobroman, and observation alone) in patients with PV who required phlebotomy to control hematocrit, had splenomegaly, and were resistant to or intolerant of hydroxyurea (Vannucchi et al., 2015). Ruxolitinib was superior to BAT for hematocrit control without phlebotomy, reduction in enlarged spleen size, and normalization of blood count (Vannucchi et al., 2015). In addition, treatment with ruxolitinib may reduce the severity of PV-related symptoms and improve

**Figure 1.** Treatment flow chart for patients with polycythemia vera. PV = polycythemia vera.

- Low dose aspirin is contraindicated in patients with extreme thrombosis (platelet count > 1,000 $\times 10^9/L$; Landolfi et al., 2004).
- Marchioli et al. (2013).
- Marchioli et al. (2005); Tefferi et al. (2013).
- Barbui et al. (2015); Marchioli et al. (2013).
- Kiladjian, Chevret, Dosquet, Chomienne, and Rain (2011).
- Quintás-Cardama et al. (2009); Sacchi et al. (1994); Silver (2006).
- Vannucchi et al. (2015).
**Brief Fatigue Inventory®**

**Instructions:** Please fill out all questions as best able, reflecting how these symptoms affected you over the **LAST WEEK** unless directed otherwise. Complete forms until STOP instruction toward the end of the packet.

| Symptom                                                                 | 1 to 10 (0 if absent) ranking                                                                 |
|-------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your fatigue right **NOW** | (No fatigue) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                     |
| Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your **USUAL level** of fatigue during past 24 hours | (No fatigue) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                     |
| Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your **WORST level** of fatigue during past 24 hours | (No fatigue) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                     |

**Circle the one number that describes how, during the past 24 hours, fatigue has interfered with your**

| General activity                                                                 | (Does not interfere) 0 1 2 3 4 5 6 7 8 9 10 (Completely interferes) |
| Mood                                                                                    | (Does not interfere) 0 1 2 3 4 5 6 7 8 9 10 (Completely interferes) |
| Walking ability                                                                          | (Does not interfere) 0 1 2 3 4 5 6 7 8 9 10 (Completely interferes) |
| Normal work (includes work both outside the home and daily chores)                     | (Does not interfere) 0 1 2 3 4 5 6 7 8 9 10 (Completely interferes) |
| Relations with other people                                                              | (Does not interfere) 0 1 2 3 4 5 6 7 8 9 10 (Completely interferes) |
| Enjoyment of life                                                                         | (Does not interfere) 0 1 2 3 4 5 6 7 8 9 10 (Completely interferes) |

© MD Anderson Cancer Center

**Myeloproliferative Neoplasm Symptom Assessment Form®**

**Circle the one number that describes how, during the past week how much difficulty you have had with each of the following symptoms**

| Symptom                                                                                   | 1 to 10 (0 if absent) ranking                                                                 |
|-------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Filling up quickly when you eat (early satiety)                                          | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| Abdominal pain                                                                            | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| Abdominal discomfort                                                                      | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| Inactivity                                                                                | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| Problems with headaches                                                                   | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| Problems with concentration – Compared to prior to my MPD                                 | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| Dizziness/vertigo/lightheadedness                                                          | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| Numbness/tingling (in my hands and feet)                                                   | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| Difficulty sleeping                                                                        | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| Depression or sad mood                                                                    | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| Problems with sexual desire or function                                                   | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| Cough                                                                                     | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| Night sweats                                                                              | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| Itching (pruritus)                                                                        | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| Bone pain (diffuse not joint pain or arthritis)                                          | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| Fever (> 100°F)                                                                           | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Daily)                                                    |
| Unintentional weight loss last 6 months                                                    | (Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst imaginable)                                         |
| What is your overall quality of life?                                                     | (As good as it can be) 0 1 2 3 4 5 6 7 8 9 10 (As bad as it can be)                       |

© Mayo Clinic

**Figure 2.** Myeloproliferative Neoplasm Symptom Assessment Form. MPD = myeloproliferative disorder. Reproduced with permission from Scherber et al. (2011).
QOL based on patient-reported outcomes (Mesa et al., 2016b; Vannucchi et al., 2015).

Adverse events with ruxolitinib were primarily grade 1 or 2, with a lower grade 3 or 4 adverse event rate (28.8 per 100 patient-years of exposure) compared with BAT (44.0 per 100 patient-years of exposure; Vannucchi et al., 2015). Among patients treated with ruxolitinib, MF and AML transformation rates were consistent with published rates for high-risk patients with PV (Finazzi et al., 2005; Passamonti et al., 2004; Vannucchi et al., 2015). Herpes zoster infections were all grade 1 or 2 and only occurred with ruxolitinib (6.4%); no patients discontinued ruxolitinib because of herpes zoster (Vannucchi et al., 2015). Nonmelanoma skin cancer occurred in more patients in the ruxolitinib arm (3.6%) compared with the BAT arm (1.8%); however, all patients in the ruxolitinib arm had a history of nonmelanoma skin cancer or precancerous lesions (Vannucchi et al., 2015). No patients died while receiving randomized treatment; two patients died for reasons that were considered unrelated to ruxolitinib treatment after crossing over to ruxolitinib from BAT.

**Case Study Continued**

Because of hydroxyurea resistance, Mr. M was evaluated for treatment with ruxolitinib. Hepatic, renal, and platelet function were noted to be within normal limits. Review of the medication profile did not reveal any potential drug-drug interactions. Therefore, he was started on ruxolitinib 10 mg twice daily. After 3 months of treatment, Mr. M maintained hematocrit control and had improvements in symptoms and leukocytosis.

Ruxolitinib exposure may be affected by hepatic and renal impairment (Chen et al., 2013), as well as concomitant treatment with a cytochrome P450 3A4 inhibitor (Shi et al., 2012), and dosing should be modified as appropriate (Incyte Corporation, 2016). Mr. M was informed about the risks for herpes zoster infections and nonmelanoma skin cancer and continues to be monitored accordingly.

**ASPECTS OF INDIVIDUALIZED PATIENT MANAGEMENT**

Advanced practitioners play a critical role in managing patients with PV. Regular patient contact enables the AP to closely monitor laboratory values to optimize medical management and to educate patients about potential disease symptoms, adverse events related to current and/or alternative treatment options, and lifestyle or treatment modifications to achieve improvements (Raedler, 2014). When dispensing medication, pharmacists are provided an opportunity to inform patients about the specifics of treatment delivery and dosing as well as potential drug-drug interactions for those patients receiving concomitant medications. Finally, APs can facilitate improved patient compliance and adherence by placing reminder phone calls to patients, offering direct-to-patient deliveries, and coordinating with health plans and patient assistance programs to facilitate payment.
PV MANAGEMENT BY APs

DISCUSSION

Patients with PV require long-term management to prolong survival and improve QOL. Familiarity with the 2008 WHO diagnostic criteria (Tefferi & Vardiman, 2008), as well as possible exceptions for masked PV (Barbui et al., 2014), will allow the AP to quickly and accurately identify patients with PV. Although nearly all patients should initially receive treatment with aspirin (Landolfi et al., 2004) and phlebotomy to achieve a target hematocrit < 45% (Barbui et al., 2011; Marchioli et al., 2013), management should evolve with the natural course of the disease (Barbui et al., 2011). Management decisions should be informed by current evidence, based on both objective measures (e.g., CBC, bone marrow biopsy, manual spleen palpation) and subjective measures (e.g., patient-reported symptoms with comprehensive instruments such as the Myeloproliferative Neoplasm Symptom Assessment Form) to identify patients who will benefit from the addition of cytoreductive treatment such as hydroxyurea (Barbui et al., 2011; Scherber et al., 2011). Knowledge of the ELN criteria for hydroxyurea resistance and intolerance (Barosi et al., 2010) will allow the AP in hematology/oncology to identify high-risk patients who may benefit from a change in therapy, including consideration of ruxolitinib (Vannucchi et al., 2015). Advanced practitioners may also identify high-risk patients in need of an alternate disease management strategy based on the IWG-MRT criteria for fibrotic transformation (Barosi et al., 2008) and the WHO criteria for leukemic transformation (Vardiman et al., 2009). Early diagnosis and evidence-based patient management by APs will promote improved outcomes and better QOL.

Acknowledgment

Editorial assistance was provided by Cory Pfeifferberger, PhD (Complete Healthcare Communi-

---

**Table 4. Approaches to the Treatment of Polycythemia Vera With Clinical Implications**

| Therapeutic intervention | Rationale | Common adverse events | Clinical implications |
|--------------------------|-----------|-----------------------|----------------------|
| Phlebotomy               | Reduce the risk of thrombotic events | Post-phlebotomy thrombosis (rare), syncope, dizziness, pallor, nausea/vomiting, iron deficiency | • Target hematocrit is < 45% • Patients may benefit from replacement of IV fluids following phlebotomy • Monitor iron parameters periodically |
| Antihistamines           | Supportive care | Somnolence | • Used to treat pruritus associated with erythrocytosis |
| Aspirin                  | Reduce the risk of thrombotic events and microvascular symptoms (i.e., ocular headaches, tinnitus, atypical chest pain, palmar/plantar erythema, and burning) | Increased risk of bruising or bleeding | • Low-dose aspirin is generally administered once daily; twice daily dosing may be considered for patients at higher risk |
| Hydroxyurea              | Cytoreductive; reduction in symptom burden | Mouth sores, leg ulcers, cytopenias | • 500 mg once or twice daily, titrate to adequate reduction in hematocrit level and platelet counts • Maximum daily dose is 2,000 mg twice daily |
| Interferon               | Cytoreductive; reduction in symptom burden | Moderately severe flu-like symptoms, confusion, depression | • Pegylated interferon-α is preferred over recombinant interferon because of the convenience of once-a-week dosing |
| Ruxolitinib              | Cytoreductive; reduction in symptom burden | Cytopenias, headache, diarrhea, fatigue, dizziness, muscle spasms | • Starting dosage: 10 mg twice daily by mouth • Requires dose modification for renal or hepatic impairment, disease control, or cytopenia |

Note. IV = intravenous. Information from Alvarez-Lárran et al. (2017); Besses and Alvarez-Larrán (2016); Hasselbalch (2011); Incyte Corporation (2016); Kiladjian, Chevret, Dosquet, Chomienne, and Rain (2011); Kim and Oh (2016); Landolfi et al. (2004); Marchioli et al. (2013); Michiels et al. (2006); Pai, Kaplan, and Giles (2016); Patel and Yosipovitch (2010); Siegel, Tauscher, and Petrides (2013); Spivak and Hasselbalch (2011); Tefferi and Barbi (2015); Vannucchi et al. (2015).
cations, LLC, an ICON plc company), whose work was funded by Incyte Corporation.

Disclosure
Ms. KURTIN received a consulting fee or honorarium from Incyte Corporation and served as a board member for The MDS Foundation without compensation. Ms. LYLE received a consulting fee or honorarium from and previously served on a speakers bureau for Incyte Corporation.

References
Alvarez-Lárran, A., Pereira, A., Cervantes, F., Arellano-Rodrigo, E., Hernández-Boluda, J. C., Ferrer-Marin, F.,...Besses, C. (2012). Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood, 119(6), 1363–1369. https://doi.org/10.1182/blood-2011-10-387787
Alvarez-Lárran, A., Pérez-Encinas, M., Ferrer-Marin, F., Hernández-Boluda, J. C., Ramírez, M. J., Martínez-López, J.,...Besses, C. (2017). Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica, 102(1), 103–109. https://doi.org/10.3324/haematol.2016.152769
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M.,...Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391–2405. https://doi.org/10.1182/blood-2016-03-643544
Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Gisslinger, H., Goff, D. C., Jr., Lloyd-Jones, D. M., Bennett, G.,...Coady, S., Kaplan, M. E., Peterson, P., Berk, D. P., & Wasserman, L. R. (1997). From efficacy to safety: Jak-Akt kinase inhibition in renal and hepatic impairment patients. European Medicines Agency. (2015). Jakavi (ruxolitinib) EU summary of product characteristics, Novartis Pharmaceuticals Corporation, Basel, Switzerland. Retrieved from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002464/human_med_001568.jsp&mid=WC0b01ac058001d124
Chen, X., Shi, J. G., Emm, T., Scherle, P. A., McGee, R. F., Lo, Y.,...Yeleswaran, S. (2013). Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCBO184242 phosphate) in renal and hepatic impairment patients. Clinical Pharmacology in Drug Development, 3(1), 34–42. https://doi.org/10.1002/cpdd.77
Emmanuel, R. M., Dueck, A. C., Geyer, H. L., Kiladjian, J. J., Slot, S., Zweegman, S.,...Mesa, R. A. (2012). Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Journal of Clinical Oncology, 30(33), 4098–4103. https://doi.org/10.1200/JCO.2012.38.368
European Medicines Agency. (2015). Jakavi (ruxolitinib) EU summary of product characteristics, Novartis Pharmaceuticals Corporation, Basel, Switzerland. Retrieved from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002464/human_med_001568.jsp&mid=WCOB01ac058001d124
Finazzi, G., Caruso, V., Marchiolli, R., Capi, G., Chiese, T., Finelli, C.,...Barbui, T. (2005). Acute leukemia in patients with polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study. Blood, 105(7), 2664–2670. https://doi.org/10.1182/blood-2004-09-3426
Fuchtmann, S. K., Mack, K., Kaplan, M. E., Peterson, P., Berk, P. D., & Wasserman, L. R. (1997). From efficacy to safety: A Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Seminars in Hematology, 34(1), 17–23.
Goff, D. C., Jr., Lloyd-Jones, D. M., Bennett, G., Coady, S., D'Agostino, R. B., Sr., Gibbons, R.,...American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014). 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 63(25 Pt B), 2935–2959. https://doi.org/10.1016/j.jacc.2013.11.005
Hasselbalch, H. C. (2011). A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Review of Hematology, 4(6), 637–655. https://doi.org/10.1586/ehm.11.63
Hulcrantz, M., Kristinsson, S. Y., Andersson, T. M., Landgren, O., Eloranta, S., Derolf, A. R.,...Björkholm, M.
(2012). Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: A population-based study. Journal of Clinical Oncology, 30(24), 2995–3001. https://doi.org/10.1200/JCO.2012.42.1925

Incyte Corporation. (2016). Jakafi (ruxolitinib) package insert. Retrieved from http://www.jakafi.com/pdf/precribing-information.pdf

Kambali, S., & Taj, A. (2016). Polycythemia vera masked due to severe iron deficiency anemia. Hematology/Oncology and Stem Cell Therapy. Advance online publication. https://doi.org/10.1016/j.hemonc.2016.08.007

Kiladjian, J. J., Chevret, S., Dosquet, C., Chomienne, C., & Rain, J. D. (2011). Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980. Journal of Clinical Oncology, 29(29), 3907–3913. https://doi.org/10.1200/JCO.2011.36.0792

Kim, K. H., & Oh, K. Y. (2016). Clinical applications of therapeutic phlebotomy. Journal of Blood Medicine, 7, 139–144. https://dx.doi.org/10.2147%2FJBBM.S108479

Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C.,....European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. (2004). Efficacy and safety of low-dose aspirin in polycythemia vera. New England Journal of Medicine, 350(2), 114–124. https://doi.org/10.1056/NEJMoa035572

Manoharan, A., Horsley, R., & Pitney, W. R. (1979). The reticulinn content of bone marrow in acute leukaemia in adults. British Journal of Haematology, 43(2), 185–190.

Marchioli, R., Finazzi, G., Landolfi, R., Kutti, J., Gisslinger, H., Patrono, C.,...Barbui, T. (2005). Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. Journal of Clinical Oncology, 23(10), 2224–2232. https://doi.org/10.1200/JCO.2005.07062

Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R., Cavazzina, R., Cilloni, D.,...CYTO-PV Collaborative Group. (2013). Cardiovascular events and intensity of treatment in polycythemia vera. New England Journal of Medicine, 368(1), 22–33. https://doi.org/10.1056/NEJMoai208500

Mehta, J., Wang, H., Iqbal, S. U., & Mesa, R. (2014). Epidemiology of myeloproliferative neoplasms in the United States. Leukemia and Lymphoma, 55(3), 595–600. https://doi.org/10.3109/10428194.2013.813500

Mesa, R., Miller, C. B., Thyne, M., Mangan, J., Goldberger, S., Fazal, S.,...Mascarenhas, J. O. (2016a). Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: The MPN Landmark survey. BMC Cancer, 16, 167. https://doi.org/10.1186/s12885-016-2208-2

Mesa, R., Verstovsek, S., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S.,...Vannucchi, A. M. (2016b). Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. European Journal of Haematology, 97(2), 192–200. https://doi.org/10.1111/ejh.12707

Michiels, J. J., Berneman, Z., Schroyens, W., Koudstaal, P. J., Lindemans, J., Neumann, H. A., & van Vliet, H. H. (2006). Platelet-mediated erythromelalgia, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: A distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets, 17(8), 528–544.

Pai, S. G., Kaplan, J. B., & Giles, F. J. (2016). Long-acting interferon for myeloproliferative neoplasms - an update. Expert Review of Hematology, 9(10), 915–917. https://doi.org/10.1080/17474086.2016.1231571

Pardanani, A., Lasho, T. L., Finke, C., Hanson, C. A., & Tefferi, A. (2007). Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia, 21(9), 1960–1963.

Parker, D. M., Deel, P. C., & Arner, S. S. (2004). Iron out the details of therapeutic phlebotomy. Nursing, 24(2), 46–47.

Passamonti, F. (2012). How I treat polycythemia vera. Blood, 120(2), 275–284. https://doi.org/10.1182/blood-2012-02-366054

Passamonti, F., Rumi, E., Pietra, D., Elena, C., Boveri, E., Arcaini, L.,...Cazzola, M. (2010). A prospective study of 338 patients with polycythemia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrinotic or leukemic disease transformation and vascular complications. Leukemia, 24(9), 1574–1579. https://doi.org/10.1038/leu.2010.148

Passamonti, F., Rumi, E., Pungolinio, E., Malabarba, L., Bertazzoni, P., Valentini, M.,...Lazzarino, M. (2004). Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. American Journal of Medicine, 117(10), 755–761. https://doi.org/10.1016/j.amjmed.2004.06.032

Patel, T., & Yosipovitch, G. (2010). Therapy of pruritus. Expert Opinion on Pharmacotherapy, 11(10), 1673–1682. https://dx.doi.org/10.1517%2F14656566.2010.484420

Quintás-Cardama, A., Kantarjian, H., Cortes, J., & Verstovsek, S. (2011). Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nature Reviews. Drug Discovery, 10(2), 127–140. https://doi.org/10.1038/nrd3264

Quintás-Cardama, A., Kantarjian, H., Manshouri, T., Luthra, R., Estrov, Z., Pierce, S.,...Verstovsek, S. (2009). Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. Journal of Clinical Oncology, 27(32), 5418–5424. https://doi.org/10.1200/JCO.2009.23.6075

Quintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A.,...Verstovsek, S. (2010). Preclinical characterization of the selective JAK1/2 inhibitor INCBO18424: Therapeutic implications for the treatment of myeloproliferative neoplasias. Blood, 115(15), 3109–3117. https://doi.org/10.1182/blood-2009-04-214957

Raedler, L. A. (2014). Diagnosis and management of polycythemia vera: Proceedings from a multidisciplinary roundtable. American Health & Drug Benefits, 7(7 suppl 3), S36–S47.

Sacchi, S., Leoni, P., Liberati, M., Riccardi, A., Tabilio, A., Tartoni, P.,...Martelli, M. F. (1994). A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. Annals of Hematology, 68(5), 247–250.

Scherber, R., Dueck, A. C., Johansson, P., Barbui, T., Barosi, G., Vannucchi, A. M.,...Mesa, R. A. (2011). The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients. Blood, 118(2), 401–408. https://doi.org/10.1182/blood-2011-01-328955
Shi, J. G., Chen, X., Emm, T., Scherle, P. A., McGee, R. F., Lo, Y.,...Yeleswaram, S. (2012). The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. *Journal of Clinical Pharmacology, 52*(6), 809–818. https://doi.org/10.1177/0091270011405663

Siegel, F. P., Tauscher, J., & Petrides, P. E. (2013). Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. *American Journal of Hematology, 88*(8), 665–669. https://doi.org/10.1002/ajh.23474

Silver, R. T. (2006). Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. *Cancer, 107*(3), 451–458. https://doi.org/10.1002/cncr.22026

Spivak, J. L., & Hasselbalch, H. (2011). Hydroxycarbamide: A user’s guide for chronic myeloproliferative disorders. *Expert Review of Anticancer Therapy, 11*(3), 403–414. https://doi.org/10.1586/era.11.10

Tefferi, A., & Barbui, T. (2015). Polycythemia vera and essential thrombocytosis: 2015 update on diagnosis, risk-stratification and management. *American Journal of Hematology, 90*(2), 162–173. https://doi.org/10.1002/ajh.23895

Tefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F.,...Barbui, T. (2013). Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. *Leukemia, 27*(9), 1874–1881. https://doi.org/10.1038/leu.2013.163

Tefferi, A., Thiele, J., Vannucchi, A. M., & Barbui, T. (2014). An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. *Leukemia, 28*(7), 1407–1413. https://doi.org/10.1038/leu.2014.35

Tefferi, A., & Vardiman, J. W. (2008). Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. *Leukemia, 22*(1), 14–22. https://doi.org/10.1038/sj.leu.2404955

Thiele, J., Kvasnicka, H. M., Pacchetti, F., Franco, V., van der Walt, J., & Orazi, A. (2005). European consensus on grading bone marrow fibrosis and assessment of cellularity. *Haematologica, 90*(8), 1128–1132.

Vannucchi, A. M. (2014). How I treat polycythemia vera. *Blood, 124*(22), 3212–3220. https://doi.org/10.1182/blood-2014-07-551929

Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F.,...Verstovsek, S. (2015). Ruxolitinib versus standard therapy for the treatment of polycythemia vera. *New England Journal of Medicine, 372*(5), 426–435. https://doi.org/10.1056/NEJMoa1409002

Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A.,...Bloomfield, C. D. (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood, 114*(5), 937–951. https://doi.org/10.1182/blood-2009-03-209262

Wians, F. H. (2015). Merck manuals professional edition - Blood tests: Normal values. Retrieved March 11, 2016, from http://www.merckmanuals.com/professional/appendixes/normal-laboratory-values/blood-tests-normal-values#v8508814